FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912141387> ?p ?o ?g. }

• W2912141387 endingPage "1067" @default.
• W2912141387 startingPage "1060" @default.
• W2912141387 abstract "Background and purpose Breakthrough disease on first‐line injectables in relapsing‐remitting multiple sclerosis ( RRMS ) is a common clinical situation where comparative studies between different escalation therapies are lacking. The aim of this study was to compare the efficacy, safety and medication persistence of natalizumab (NTZ), rituximab (RTX) and fingolimod (FGL) as escalation therapy in RRMS . Methods Patients switching from interferon or glatiramer acetate to NTZ, RTX or FGL due to breakthrough disease were identified through the Swedish multiple sclerosis ( MS ) registry at four large MS centers in this retrospective observational study. Data were collected from the MS registry and medical charts. Hazard ratios ( HR s) for relapses, adverse events and drug discontinuation with 95% confidence interval ( CI ) were calculated using multivariable confounder‐adjusted Cox proportional hazard models. Results A total of 241 patients were included. The annualized relapse rates were 0.02 for NTZ, 0.03 for RTX and 0.07 for FGL. Compared with NTZ, the adjusted HR for relapse was 1.0 (95% CI , 0.2–5.6) for RTX and 3.4 (95% CI , 1.3–9.2) for FGL. The annualized drug discontinuation rates were 0.15, 0.01 and 0.15 for NTZ, RTX and FGL, respectively. The adjusted HR for drug discontinuation was 0.05 (95% CI , 0.01–0.38) for RTX and 1.0 (95% CI , 0.6–1.7) for FGL vs. NTZ. Conclusions In patients with RRMS on interferon/glatiramer acetate with breakthrough disease, switching to NTZ or RTX was associated with less disease activity compared with FGL. RTX displayed superior medication persistence compared with both NTZ and FGL." @default.
• W2912141387 created "2019-02-21" @default.
• W2912141387 creator A5000664165 @default.
• W2912141387 creator A5012945005 @default.
• W2912141387 creator A5041446091 @default.
• W2912141387 creator A5043977705 @default.
• W2912141387 creator A5057206152 @default.
• W2912141387 creator A5065975430 @default.
• W2912141387 creator A5081657251 @default.
• W2912141387 creator A5086810017 @default.
• W2912141387 creator A5088196059 @default.
• W2912141387 date "2019-03-12" @default.
• W2912141387 modified "2023-10-02" @default.
• W2912141387 title "Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis" @default.
• W2912141387 cites W1803778850 @default.
• W2912141387 cites W2041351053 @default.
• W2912141387 cites W2044022462 @default.
• W2912141387 cites W2087283639 @default.
• W2912141387 cites W2107008240 @default.
• W2912141387 cites W2114360739 @default.
• W2912141387 cites W2128600935 @default.
• W2912141387 cites W2141111992 @default.
• W2912141387 cites W2159712156 @default.
• W2912141387 cites W2274125150 @default.
• W2912141387 cites W2313484897 @default.
• W2912141387 cites W2405536231 @default.
• W2912141387 cites W2463810424 @default.
• W2912141387 cites W2536452417 @default.
• W2912141387 cites W2561881161 @default.
• W2912141387 cites W2565433170 @default.
• W2912141387 cites W2784268727 @default.
• W2912141387 cites W2801606837 @default.
• W2912141387 doi "https://doi.org/10.1111/ene.13936" @default.
• W2912141387 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30762259" @default.
• W2912141387 hasPublicationYear "2019" @default.
• W2912141387 type Work @default.
• W2912141387 sameAs 2912141387 @default.
• W2912141387 citedByCount "25" @default.
• W2912141387 countsByYear W29121413872019 @default.
• W2912141387 countsByYear W29121413872020 @default.
• W2912141387 countsByYear W29121413872021 @default.
• W2912141387 countsByYear W29121413872022 @default.
• W2912141387 countsByYear W29121413872023 @default.
• W2912141387 crossrefType "journal-article" @default.
• W2912141387 hasAuthorship W2912141387A5000664165 @default.
• W2912141387 hasAuthorship W2912141387A5012945005 @default.
• W2912141387 hasAuthorship W2912141387A5041446091 @default.
• W2912141387 hasAuthorship W2912141387A5043977705 @default.
• W2912141387 hasAuthorship W2912141387A5057206152 @default.
• W2912141387 hasAuthorship W2912141387A5065975430 @default.
• W2912141387 hasAuthorship W2912141387A5081657251 @default.
• W2912141387 hasAuthorship W2912141387A5086810017 @default.
• W2912141387 hasAuthorship W2912141387A5088196059 @default.
• W2912141387 hasConcept C126322002 @default.
• W2912141387 hasConcept C167135981 @default.
• W2912141387 hasConcept C203014093 @default.
• W2912141387 hasConcept C207103383 @default.
• W2912141387 hasConcept C2776036978 @default.
• W2912141387 hasConcept C2778577042 @default.
• W2912141387 hasConcept C2778715236 @default.
• W2912141387 hasConcept C2779338263 @default.
• W2912141387 hasConcept C2780640218 @default.
• W2912141387 hasConcept C2780653079 @default.
• W2912141387 hasConcept C2781004633 @default.
• W2912141387 hasConcept C44249647 @default.
• W2912141387 hasConcept C50382708 @default.
• W2912141387 hasConcept C71924100 @default.
• W2912141387 hasConceptScore W2912141387C126322002 @default.
• W2912141387 hasConceptScore W2912141387C167135981 @default.
• W2912141387 hasConceptScore W2912141387C203014093 @default.
• W2912141387 hasConceptScore W2912141387C207103383 @default.
• W2912141387 hasConceptScore W2912141387C2776036978 @default.
• W2912141387 hasConceptScore W2912141387C2778577042 @default.
• W2912141387 hasConceptScore W2912141387C2778715236 @default.
• W2912141387 hasConceptScore W2912141387C2779338263 @default.
• W2912141387 hasConceptScore W2912141387C2780640218 @default.
• W2912141387 hasConceptScore W2912141387C2780653079 @default.
• W2912141387 hasConceptScore W2912141387C2781004633 @default.
• W2912141387 hasConceptScore W2912141387C44249647 @default.
• W2912141387 hasConceptScore W2912141387C50382708 @default.
• W2912141387 hasConceptScore W2912141387C71924100 @default.
• W2912141387 hasIssue "8" @default.
• W2912141387 hasLocation W29121413871 @default.
• W2912141387 hasLocation W29121413872 @default.
• W2912141387 hasOpenAccess W2912141387 @default.
• W2912141387 hasPrimaryLocation W29121413871 @default.
• W2912141387 hasRelatedWork W2082301205 @default.
• W2912141387 hasRelatedWork W2083083635 @default.
• W2912141387 hasRelatedWork W2085438061 @default.
• W2912141387 hasRelatedWork W2773318060 @default.
• W2912141387 hasRelatedWork W3085502568 @default.
• W2912141387 hasRelatedWork W31195842 @default.
• W2912141387 hasRelatedWork W3207019851 @default.
• W2912141387 hasRelatedWork W4292433363 @default.
• W2912141387 hasRelatedWork W4320179558 @default.
• W2912141387 hasRelatedWork W2264939213 @default.
• W2912141387 hasVolume "26" @default.
• W2912141387 isParatext "false" @default.

• next